Navigation Links
Hospira Announces FDA Approval of Topotecan Injection
Date:2/3/2011

LAKE FOREST, Ill., Feb. 3, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United States. The medication is a generic version of Hycamtin®, which had 2010 U.S. sales of more than $140 million. Hospira's topotecan is indicated for treatment of small cell lung cancer (SCLC) sensitive disease after failure of first-line chemotherapy.  

The solution formulation of topotecan, with a concentration of 4 mg/4 ml, is designed to improve caregiver convenience and safety, and Hospira expects to launch the product by the end of February.

"Hospira's solution version of topotecan expands our portfolio of value-added generics," said Thomas Moore, president, U.S., Hospira. "We're excited to offer the medical community access to a lower-cost, more convenient version of this key oncolytic."

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage™ drug delivery system and iSecure™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. Hospira Reports Third-Quarter 2009 Results
7. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
8. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
9. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
10. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
11. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Syneron Medical Ltd. (NASDAQ: ELOS ... that its new PicoWay® device has received CE Mark ... and pigmented lesions on any skin type. PicoWay is ... and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay technology ... are trillionths of a second, known as picosecond pulses. ...
(Date:7/28/2014)... (NYSE: RMD ), an innovator and pioneer ... and other chronic respiratory conditions, has won a permanent ... medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales ... 220 masks.  The judgment was entered by the Regional ... appealable, and applies throughout Germany.  The ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 ... to meet with Linde,s Healthcare division experts at ... held at McCormick Place in Chicago, Illinois ... demand nothing less than complete confidence in a reliable ... Healthcare Segment manager. "Linde understands the importance of this ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Eli Lilly and Company,s (NYSE: LLY ... set to launch. Through the program, the company is ... that often lack basic resources. While serving others, the ... of different cultures and see firsthand the complex problems ...
... 2011 Patient Safety Technologies, Inc. (the "Company") (OTC ... closing of a $7.1 million common stock financing.  The ... several existing shareholders and certain members of senior management, ... price of $0.75 per share.  Proceeds from the offering ...
Cached Medicine Technology:Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 2Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 3Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 4Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 5Patient Safety Technologies, Inc. Closes $7.1 Million Common Stock Offering 2
(Date:7/28/2014)... An estimated 68,000 women and men ... and prostate cancers – an aggressive form of the ... other parts of the body, such as the lungs, ... University College of Medicine have developed a compound ... progression by blocking tumor cells from “re-seeding.” Their discovery ...
(Date:7/28/2014)... Randy Dotinga HealthDay ... Scientists know it takes humans just milliseconds to look at ... Now, a new study finds that certain facial features seem ... The shape and size of the mouth, for example, ... dimensions are keys to attractiveness. The study findings ...
(Date:7/28/2014)... treat severe chronic migraine headaches led to significant symptom ... patients treated at Massachusetts General Hospital (MGH). Physicians ... report that more than half of 35 patients treated ... headaches associated with compression of craniofacial nerves reported ... paper has received advance online publication in the journal ...
(Date:7/28/2014)... 2014 Thousands of DePuy Pinnacle hip ... individuals who were allegedly injured by a metal-on-metal version ... forward in U.S. District Court, Northern District of Texas, ... on July 18, 2014, U.S. District Judge Ed Kinkeade ... Plaintiffs’ Steering Committee that sought the deposition of a ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Glutamine is ... and it’s considered to be conditionally essential during times ... is an advanced recovery & Immune System Support. , ... glutamine your body produces, supplementing with additional glutamine may ... waste products in the body, digestion and immune system ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... be involved in decisions regarding quality of the donor ... a higher risk of failure, according to research by ... of patients would choose to remain on the waiting ... to the study,s lead author Michael L. Volk, M.D., ...
... (HealthDay News) -- ,The timing of an operation doesn,t affect ... study finds. For example, there,s no difference in death ... morning or on Monday instead of Friday, the researchers said. ... lead to a higher rate of safety problems when operations ...
... with obstructive sleep apnea are more likely to stick ... involved with their treatment, according to a team of ... airway collapses during sleep. It is the most common ... become more elevated in obese people. The first line ...
... Optimism is associated with higher grades for female students, but ... at Ben-Gurion University of the Negev in Israel assessed the ... 72 percent female) aged 20 to 28. The investigators ... grades than those who were less optimistic. However, high levels ...
... a chronic swelling condition common in breast cancer survivors, ... past, most people believed that exercise might induce or ... researchers say the benefits of exercise outweigh the risks ... Jane Armer, professor in the Sinclair School of Nursing, ...
... issue of Hepatology , a journal of the ... uncovered limitations in screening for primary liver cancer, also ... that, if given the choice during a clinical trial, ... of non-screening, therefore making a randomized study of HCC ...
Cached Medicine News:Health News:Transplant candidates seek best quality livers, even if it means waiting longer 2Health News:Time of Surgery Doesn't Influence Results, Study Says 2Health News:Innovative approaches help sleep apnea sufferers benefit from CPAP 2Health News:MU researchers recommend exercise for breast cancer survivors, lymphedema patients 2Health News:Studies of patients with cirrhosis uncover limitations in liver cancer screening 2
Irrigation pump for arthroscopy....
... DVD Burner captures still images and ... patient archives allows for multiple cases ... The unit provides software burned to ... playback and editing. Compatible with DICOM ...
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements....
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty....
Medicine Products: